DGAP-News: Sanochemia Pharmazeutika AG concludes exclusive distribution agreement with Iberoinvesa
(firmenpresse) - Sanochemia Pharmazeutika AG / Alliance/Contract
30.06.2010 08:01
Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
* SANOCHEMIA concludes exclusive distribution agreement for radiological
products in Spain, Portugal and Latin America
* Dynamic sales activities with Iberoinvesa already initiated
Vienna, 30 June 2010 - Sanochemia Pharmazeutika AG, Vienna, has concluded
an exclusive distribution agreement with Iberoinvesa Pharma SL, Madrid,
covering Spain, Portugal and Latin America. By means of this agreement and
the launch in Spain, Sanochemia not only paves the way for the fast-track
development of markets for its entire radiological product portfolio in
Spain and Portugal but also for rapid access to selected markets in Latin
America such as Columbia, Mexico and the Dominican Republic.
Iberoinvesa Pharma SL is a young Spanish drugs company which has
specialised exclusively in the distribution of radiological products
(x-ray, CT and MRT imaging agents). The company was founded by leading
individuals from the field of radiology who have the necessary expertise
and local market knowledge but who, as a result of mergers involving their
previous companies, lacked both distribution licenses and products. As a
competent partner, Sanochemia is now providing ready-to-market products
while Iberoinvesa, for its part, is making available top personnel with
many years of experience in the areas of regulatory affairs and sales in
the territories covered by the agreement in what appears to be an optimal
synergy.
Launches in Spain and Latin America
The successful launch of Secrelux(R), Sanochemia's pancreas diagnostic, has
demonstrated the high degree of acceptance enjoyed by high quality, safe
and cost-effective products. Further product launches involving the
speciality imaging agents Scanlux(R) and Magnetolux(R) are planned for
October / November 2010. Spain is a major and attractive market in Europe
with a population approaching 50 million. The current market potential for
radiological products in Spain lies between around 60 and 70 million euro,
albeit with differing growth rates in the various segments. In the mid
term, Sanochemia forecasts a market share of 5 - 10%.
Furthermore, Spain acts as the 'door to South America' - a springboard for
planned expansion into Latin America. Given that the emerging markets of
Latin America are expected to experience sharp rises in demand in terms of
their healthcare systems and are countries in which medical care is a
rising priority, this region of the world promises to be an attractive
sales area for Sanochemia.
'We are very motivated by the launch in Spain and the above-average growth
in terms of market potential in these emerging markets', says Werner
Frantsits, CEO and CFO of Sanochemia, 'this is driving us to intensify our
efforts to develop these markets. Our plan of securing the first sales of
products in South America via Spain as early as this calendar year appears
absolutely realistic and the signs are that rapid progress is already being
made in terms of preparing the market.'
Margarita Hoch
Investor Relations
Tel.: +43 / 1 / 3191456 / 335
Fax: +43 / 1 / 3191456 / 344
m.hoch(at)sanochemia.at
30.06.2010 08:01 Ad hoc announcement, Financial News and Media Release distributed by DGAP. Medienarchiv atwww.dgap-medientreff.deandwww.dgap.de---------------------------------------------------------------------------
Language: English
Company: Sanochemia Pharmazeutika AG
Boltzmanngasse 9a - 11
A-1091 WienÖsterreich
Phone: +43 (1) 319 14 56-0
Fax: +43 (1) 319 14 56-44
E-mail: office(at)sanochemia.at
Internet: www.sanochemia.at
ISIN: AT0000776307
WKN: 919963
Indices: Prime Standard
Listed: Regulierter Markt in Frankfurt (General Standard);
Freiverkehr in Berlin, München, Düsseldorf, Stuttgart,
Hamburg
End of News DGAP News-Service
---------------------------------------------------------------------------
Datum: 30.06.2010 - 08:01 Uhr
Sprache: Deutsch
News-ID 23208
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 335 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Sanochemia Pharmazeutika AG concludes exclusive distribution agreement with Iberoinvesa"
steht unter der journalistisch-redaktionellen Verantwortung von
Sanochemia Pharmazeutika AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
